Ginkgo Bioworks Collaborates With STRM.BIO And University Of British Columbia To Develop In Vivo Chimeric Antigen Receptor Therapies For Autoimmune Diseases

Ginkgo Bioworks Holdings, Inc. Class A +1.62%

Ginkgo Bioworks Holdings, Inc. Class A

DNA

6.90

+1.62%

Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-

specific, and highly potent in vivo CAR therapies for autoimmune diseases

BOSTON, Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The partnership aims to develop in vivo chimeric antigen receptor (CAR) therapies for autoimmune diseases, leveraging Ginkgo's expertise in RNA construct design and immune cell engineering.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.